
It is now exactly two years since pharmaceutical organization Orifarm announced the acquisition of 110 drugs from Japanese firm Takeda for EUR 615m, a deal that was officially completed in March last year.
The record-breaking takeover, which included two Takeda factories, one in Danish city Hobro and another in Łyszkowice, Poland, catapulted family owned Orifarm to the upper echelons of Danish pharmaceutical companies – both financially and in terms of the market.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app